Dextran sulfate sodium salt (MW 6500-10000)

Dextran sulfate sodium salt (DSS) (MW 6500-10000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 6500-10000) has antiviral activity against HIV-1 and HIV-2. Dextran sulfate sodium salt (MW 6500-10000) blocks the binding of virions to CD4⁺ T lymphocytes and inhibits syncytia formation. Dextran sulfate sodium salt (MW 6500-10000) also prevents experimental urolithiasis due to its cytoprotective actions. Moreover, because of its biocompatible and highly charged properties, Dextran sulfate sodium salt (MW 6500-10000) is a suitable choice for pharmaceutical systems[1][2][3][4][5][6].

Product Specifications

CAS Number

[9011-18-1]

Product Name Alternative

DSS (MW 6500-10000) ; DXS (MW 6500-10000)

UNSPSC

12352200

Target

HIV

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology

Smiles

[Dextransulfatesodiumsalt]

Molecular Weight

6500-10000

References & Citations

[1]1. Mitsuya H, et al. Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science. 1988 Apr 29;240 (4852) :646-9.|[2]2. Tostes V, et al. Low-molecular-weight dextran sulfate prevents experimental urolithiasis in rats. Clin Chim Acta. 2004 Mar;341 (1-2) :147-55. |[3]3. Lu G, et al. Dextran Sulfate Protects Pancreatic β-Cells, Reduces Autoimmunity, and Ameliorates Type 1 Diabetes. Diabetes. 2020 Aug;69 (8) :1692-1707. |[4]4. Tu C, et al. Paramagnetic, silicon quantum dots for magnetic resonance and two-photon imaging of macrophages. J Am Chem Soc. 2010 Feb 17;132 (6) :2016-23. |[5]5. Diego Carballares, et al. Preparation of a Six-Enzyme Multilayer Combi-Biocatalyst: Reuse of the Most Stable Enzymes after Inactivation of the Least Stable One. ACS Sustainable Chemistry & Engineering. 10 (1) . |[6]6. Gui Z, et al. Prolonged melittin release from polyelectrolyte-based nanocomplexes decreases acute toxicity and improves blood glycemic control in a mouse model of type II diabetes. Int J Pharm. 2020 Mar 15;577:119071.